Publications by the researcher in collaboration with Edurne San José Enériz (27)

2021

  1. Design and Synthesis of Novel Epigenetic Inhibitors Targeting Histone Deacetylases, DNA Methyltransferase 1, and Lysine Methyltransferase G9a with in Vivo Efficacy in Multiple Myeloma

    Journal of Medicinal Chemistry, Vol. 64, Núm. 6, pp. 3392-3426

2019

  1. Inhibition of a G9a/DNMT network triggers immune-mediated bladder cancer regression

    Nature Medicine

2018

  1. Detailed Exploration around 4-Aminoquinolines Chemical Space to Navigate the Lysine Methyltransferase G9a and DNA Methyltransferase Biological Spaces

    Journal of Medicinal Chemistry, Vol. 61, Núm. 15, pp. 6546-6573

  2. Discovery of Reversible DNA Methyltransferase and Lysine Methyltransferase G9a Inhibitors with Antitumoral in Vivo Efficacy

    Journal of Medicinal Chemistry, Vol. 61, Núm. 15, pp. 6518-6545

2017

  1. An in-silico approach to predict and exploit synthetic lethality in cancer metabolism

    Nature Communications, Vol. 8, Núm. 1

  2. In-silico gene essentiality analysis of polyamine biosynthesis reveals APRT as a potential target in cancer

    Scientific Reports, Vol. 7, Núm. 1

  3. Reversible dual inhibitor against G9a and DNMT1 improves human iPSC derivation enhancing MET and facilitating transcription factor engagement to the genome

    PLoS ONE, Vol. 12, Núm. 12

2012

  1. Down-regulated expression of hsa-miR-181c in Fanconi anemia patients: Implications in TNFα regulation and proliferation of hematopoietic progenitor cells

    Blood, Vol. 119, Núm. 13, pp. 3042-3049

  2. Epigenetic regulation of Wnt-signaling pathway in acute lymphoblastic leukemia (Blood (2007) 109, 8 (3462-3469))

    Blood

  3. Preclinical activity of LBH589 alone or in combination with chemotherapy in a xenogeneic mouse model of human acute lymphoblastic leukemia

    Leukemia, Vol. 26, Núm. 7, pp. 1517-1526

2011

  1. Frequent and simultaneous epigenetic inactivation of TP53 pathway genes in Acute Lymphoblastic Leukemia

    PLoS ONE, Vol. 6, Núm. 2

2009

  1. Epigenetic down-regulation of BIM expression is associated with reduced optimal responses to imatinib treatment in chronic myeloid leukaemia

    European Journal of Cancer, Vol. 45, Núm. 10, pp. 1877-1889

  2. Epigenetic regulation of MicroRNAs in acute lymphoblastic leukemia

    Journal of Clinical Oncology, Vol. 27, Núm. 8, pp. 1316-1322

  3. Epigenetic silencing of the tumor suppressor microRNA Hsa-miR-124a regulates CDK6 expression and confers a poor prognosis in acute lymphoblastic leukemia

    Cancer Research, Vol. 69, Núm. 10, pp. 4443-4453

  4. MicroRNA expression profiling in Imatinib-resistant Chronic Myeloid Leukemia patients without clinically significant ABL1-mutations

    Molecular Cancer, Vol. 8, pp. 69

2008

  1. BCR-ABL1-induced expression of HSPA8 promotes cell survival in chronic myeloid leukaemia

    British Journal of Haematology, Vol. 142, Núm. 4, pp. 571-582

  2. Down-regulation of hsa-miR-10a in chronic myeloid leukemia CD34+ cells increases USF2-mediated cell growth

    Molecular Cancer Research, Vol. 6, Núm. 12, pp. 1830-1840

  3. Methylation status of Wnt signaling pathway genes affects the clinical outcome of Philadelphia-positive acute lymphoblastic leukemia

    Cancer Science, Vol. 99, Núm. 9, pp. 1865-1868

  4. Repetitive DNA hypomethylation in the advanced phase of chronic myeloid leukemia

    Leukemia Research, Vol. 32, Núm. 3, pp. 487-490

  5. Resistance to Imatinib Mesylate-induced apoptosis in acute lymphoblastic leukemia is associated with PTEN down-regulation due to promoter hypermethylation

    Leukemia Research, Vol. 32, Núm. 5, pp. 709-716